Apollomics Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% Posted on 2023-10-232024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 Posted on 2023-10-162024-03-13 by maxproadmin More >>
Apollomics Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference Posted on 2023-09-062023-09-28 by maxproadmin More >>
Arthrosi Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study Posted on 2023-08-182023-09-28 by maxproadmin More >>
Arthrosi ARTHROSI SECURES $75M IN SERIES D FINANCING Posted on 2023-07-112023-09-28 by maxproadmin More >>
Apollomics Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium Posted on 2023-04-112023-09-28 by maxproadmin More >>
Apollomics Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq Posted on 2023-03-302023-05-30 by maxproadmin More >>
Arthrosi ARTHROSI ANNOUNCES POSITIVE TOPLINE RESULTS FOR AR882 PHASE 2B STUDY Posted on 2023-01-052023-05-30 by maxproadmin More >>
Apollomics Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations Posted on 2022-11-152023-01-07 by maxproadmin More >>
Maxpro News Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination Posted on 2022-10-142022-11-24 by maxproadmin More >>